73 Ipilimumab and Nivolumab for mesothelioma: a real-world UK tertiary centre experience

Ipilimumab and Nivolumab (IPI/NIVO) has been reimbursed as 1st line treatment for patients with mesothelioma in the UK since July 2022 based on the CHECKMATE 743 study, which demonstrated survival benefit of IPI/NIVO over chemotherapy, largely driven by improvement in non-epithelioid subgroup. Toxicity profile was consistent with use of this regimen in other malignancies.

Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: David John McMahon, Trisha Patel, Rehab Ahmed, Alexius John, Elizabeth Cartwright, Thubeena Manickavasagar, Charlotte Milner-Watts, Abu Taher, Cheryl Estall, Nadia Yousaf, Sanjay Popat, Mary O Brien, Michael Davidson, Jaishree Bhosle, Anna Minchom, Nadza Tags: Mesothelioma Source Type: research